达沙替尼
医学
血小板
内科学
胃肠病学
凝血病
不利影响
出血时间
胃肠道出血
血液学
出血素质
酪氨酸激酶
血小板聚集
受体
作者
Louise Kostos,Kate Burbury,Gaurav Srivastava,H. Miles Prince
出处
期刊:Platelets
[Informa]
日期:2015-06-01
卷期号:26 (8): 809-811
被引量:28
标识
DOI:10.3109/09537104.2015.1049138
摘要
Bleeding in patients with chronic myeloid leukaemia (CML) receiving the second-line tyrosine kinase inhibitor (TKI) dasatinib is a well-documented side effect, occurring in up to 24% of patients. In most cases, it is attributed directly to a secondary grade 3 or 4 thrombocytopaenia. Platelet dysfunction precipitated by dasatinib has been demonstrated in multiple in vitro and in vivo studies; however, there is currently no correlative data that definitively associates this with clinically significant bleeding. In this case, we report a patient with chronic-phase CML receiving dasatinib who developed significant gastrointestinal bleeding secondary to angiodysplasia in the absence of a severe thrombocytopaenia or coagulopathy. Platelet function testing on the PFA-100 assay and formal platelet aggregometry demonstrated impaired platelet aggregation, however, upon cessation of dasatinib, platelet function normalised and the bleeding resolved without further intervention. This case demonstrates that dasatinib-induced platelet dysfunction can cause clinically significant bleeding and highlights the need for physicians to be aware of this adverse effect.
科研通智能强力驱动
Strongly Powered by AbleSci AI